Merck & Co., Inc. (NYSE:MRK) Sets New 1-Year High on Analyst Upgrade

Merck & Co., Inc. (NYSE:MRK) hit a new 52-week high during trading on Thursday after Daiwa Securities Group upgraded the stock from a neutral rating to an outperform rating. Daiwa Securities Group now has a $143.00 price target on the stock. Merck & Co., Inc. traded as high as $135.68 and last traded at $135.5750, with a volume of 8874817 shares changing hands. The stock had previously closed at $132.92.

MRK has been the topic of several other reports. CICC Research initiated coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target on the stock. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Bank of America boosted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Guggenheim raised their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.50.

Insider Activity

In other news, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 137,923 shares of company stock worth $17,908,943. 0.17% of the stock is owned by company insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support the shares: Daiwa Securities raised Merck to “outperform” with a $143 price target, while Argus maintained a “buy” rating and lifted its target to $145. These actions reinforce the view that Merck’s recent momentum can continue. Merck analyst price target article
• Positive Sentiment: Keytruda and the core business remain strong: Merck’s second-quarter growth was driven primarily by Keytruda demand in early-stage and metastatic cancers, oncology products, new launches and Animal Health. Quarterly revenue of $16.61 billion exceeded the $16.37 billion consensus estimate, and revenue increased 5.1% year over year. Merck second-quarter earnings call article
• Positive Sentiment: Pipeline diversification is advancing: The FDA and European Medicines Agency accepted applications for broader ENFLONSIA use to prevent RSV in vulnerable young children. Expanded approval could create an additional growth avenue beyond oncology as Keytruda approaches eventual patent expiration. Merck ENFLONSIA RSV regulatory review article
• Neutral Sentiment: Earnings expectations are stable to slightly improved: Erste Group raised its FY2026 EPS estimate to $2.75 from $2.70, close to the roughly $2.77 consensus. Merck also declared its regular $0.85 quarterly dividend, or $3.40 annualized.
• Negative Sentiment: Keytruda concentration remains the main risk: Analysts caution that patent loss and increasing competition could eventually slow the drug’s sales growth, making the company’s pipeline and newer products increasingly important. Keytruda growth outlook article
• Negative Sentiment: Recent insider selling may temper sentiment: EVP Richard Deluca disclosed sales totaling more than 45,000 shares across transactions from August 10–12, while retaining a substantial position. The sales are not necessarily a fundamental signal, but could modestly weigh on investor confidence.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth $3,997,933,000. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Cardano Risk Management B.V. purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at about $1,012,530,000. Jennison Associates LLC bought a new position in Merck & Co., Inc. during the fourth quarter worth about $585,192,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Merck & Co., Inc. by 37.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after purchasing an additional 5,152,069 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

The firm’s 50 day moving average price is $124.94 and its two-hundred day moving average price is $119.64. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market cap of $334.49 billion, a PE ratio of 108.46, a P/E/G ratio of 5.62 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the firm earned $2.13 EPS. Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.5%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.